Coral Laboratories Ltd
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
- Market Cap ₹ 176 Cr.
- Current Price ₹ 492
- High / Low ₹ 896 / 443
- Stock P/E 9.54
- Book Value ₹ 563
- Dividend Yield 0.30 %
- ROCE 17.4 %
- ROE 13.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.89 times its book value
- Company has delivered good profit growth of 28.2% CAGR over last 5 years
- Company's working capital requirements have reduced from 182 days to 140 days
Cons
- Company has a low return on equity of 9.21% over last 3 years.
- Earnings include an other income of Rs.8.82 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 102 | |
41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 84 | |
Operating Profit | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 18 |
OPM % | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 17% |
1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 9 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 24 |
Tax % | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | |
8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 18 | |
EPS in Rs | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 50.14 |
Dividend Payout % | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 10% |
3 Years: | 15% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 28% |
3 Years: | 44% |
TTM: | -19% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 6% |
3 Years: | 25% |
1 Year: | -38% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 |
0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 | |
10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | |
Total Liabilities | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
Investments | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 |
40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | |
Total Assets | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 0 | 5 | 11 | 13 | -1 | -4 | 1 | 6 | 13 | -5 | -1 | |
1 | -0 | -3 | -10 | -13 | 3 | -2 | -0 | -6 | -3 | 1 | -0 | |
0 | -0 | -0 | 0 | -3 | -1 | 4 | 0 | 0 | -6 | 0 | 3 | |
Net Cash Flow | 2 | -0 | 2 | 1 | -2 | 1 | -2 | 1 | 0 | 4 | -4 | 1 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 |
Inventory Days | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 |
Days Payable | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 |
Cash Conversion Cycle | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 |
Working Capital Days | 158 | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 |
ROCE % | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% |
Documents
Announcements
-
Outcome Of The Board Meeting Held On October 13, 2025 For Capacity Expansion At The Plant Located At Dehradun
Corrigendum To Announcement Under Regulation 30 Of The SEBI (LODR), 2015
13 Oct - Board approved Dehradun plant addition: ointment capacity +360,000 kg, Rs30 crore investment, six-month implementation.
-
Intimation Regarding Capacity Addition Under Regulation 30 (Read With Part A Of Schedule III) Of The SEBI (LODR) Regulations, 2015
13 Oct - Board approved Dehradun ointment capacity addition 360,000 kg in 6 months; investment ~Rs 30 crore.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 13, 2025 For Capacity Expansion At The Plant Located At Dehradun
13 Oct - Board approves Dehradun capacity addition: 360,000 kg ointment, ~₹30 crore investment, within six months.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 Please find attached herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, …
-
Combined Scrutinizer Report For Remote E-Voting And Voting At The AGM Carried Out For The 43Rd Annual General Meeting Of The Company Held On Friday, September 26, 2025.
26 Sep - 43rd AGM (26 Sep 2025): Resolutions 1–9 passed; resolution 10 rejected; dividend declared.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CLL is an ISO 9001:2008 certified manufacturer and exporter of pharmaceutical formulations like tablets, capsules, liquid, and topical preparations. It focuses on generics, troubleshooting existing products, and patent noninfringing products for emerging markets.